LON:TCF Theracryf (TCF) Share Price, News & Analysis GBX 0.20 +0.00 (+1.50%) As of 08/5/2026 12:34 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About Theracryf Stock (LON:TCF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Theracryf alerts:Sign Up Key Stats Today's Range 0.19▼ 0.2150-Day Range 0.19▼ 0.2552-Week Range 0.18▼ 0.30Volume2.12 million shsAverage Volume5.39 million shsMarket Capitalization£4.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview TheraCryf plc is a biotechnology company developing new medicines for addiction and other disorders of the brain, areas of significant unmet medical need within central nervous system (CNS) disorders. The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders. The programme is heavily de-risked, demonstrates superior selectivity and high receptor occupancy, and is fully funded through to clinical readiness, with regulatory submissions targeted for 2026. TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01. TheraCryf operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with larger pharmaceutical or biotechnology companies. Read More Receive TCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theracryf and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TCF Stock News HeadlinesTheraCryf appoints new board member, issues optionsMay 2, 2025 | uk.investing.comTheracryf Plc (TCF.L)January 18, 2025 | ca.finance.yahoo.com1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-known name may be positioned to benefit while the Magnificent 7 stumbles. Smaller, overlooked stocks are showing growing potential to challenge AI's biggest players. One specific ticker stands out heading into that date.August 6 at 1:00 AM | Chaikin Analytics (Ad)Theracryf PLC Share Chat (TCF)January 13, 2025 | lse.co.ukSee More Headlines TCF Stock Analysis - Frequently Asked Questions How have TCF shares performed this year? Theracryf's stock was trading at GBX 0.18 at the beginning of the year. Since then, TCF shares have increased by 10.9% and is now trading at GBX 0.20. How were Theracryf's earnings last quarter? Theracryf Plc (LON:TCF) issued its quarterly earnings results on Wednesday, December, 3rd. The company reported ($6.00) earnings per share (EPS) for the quarter. Theracryf had a negative net margin of 792.17% and a negative trailing twelve-month return on equity of 37.30%. How do I buy shares of Theracryf? Shares of TCF stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Company Calendar Last Earnings12/03/2025Today8/06/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorFinance Industry Banks Sub-IndustryRegional Banks Current SymbolLON:TCF CIKN/A Webtheracryf.com Phone44-1625-315-090FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£5.45 million Net Margins-792.17% Pretax MarginN/A Return on Equity-37.30% Return on Assets-48.26% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 0.85 per share Price / Book0.24Miscellaneous Outstanding Shares2,148,964,000Free FloatN/AMarket Cap£4.36 million OptionableN/A Beta1.41 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (LON:TCF) was last updated on 8/6/2026 by MarketBeat.com Staff. From Our PartnersCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredNvidia's CEO says this small device is critical for AI growthA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...Brownstone Research | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredWhite House Insider: “President Trump is Getting Backstabbed!”A high-level White House insider and lifelong friend of the Trump family recently went on camera with a warnin...Paradigm Press | SponsoredThis under $7 stock could be.Just one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades ...Freedom Financial | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theracryf Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Theracryf With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
